Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OYST

Oyster Point Pharma (OYST) Stock Price, News & Analysis

Oyster Point Pharma logo

About Oyster Point Pharma Stock (NASDAQ:OYST)

Advanced Chart

Key Stats

Today's Range
$11.17
$11.17
50-Day Range
$11.08
$11.20
52-Week Range
$3.46
$19.00
Volume
330 shs
Average Volume
212,171 shs
Market Capitalization
$299.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Receive OYST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

OYST Stock News Headlines

Want to target extra income every week?
Hey, if you’d like to see a “no sweat” way to earn extra income as soon as this week, this FREE briefing could be just the thing you need…
Scotiabank Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
See More Headlines

OYST Stock Analysis - Frequently Asked Questions

Oyster Point Pharma, Inc. (NASDAQ:OYST) released its earnings results on Thursday, November, 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.48. The firm had revenue of $17.94 million for the quarter. Oyster Point Pharma had a negative trailing twelve-month return on equity of 490.33% and a negative net margin of 901.99%.

Oyster Point Pharma (OYST) raised $85 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oyster Point Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/04/2021
Today
1/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OYST
Fax
N/A
Employees
303
Year Founded
N/A

Profitability

Net Income
$-100,660,000.00
Net Margins
-901.99%
Pretax Margin
-901.99%

Debt

Sales & Book Value

Annual Sales
$24.54 million
Book Value
$3.80 per share

Miscellaneous

Free Float
22,039,000
Market Cap
$299.85 million
Optionable
Not Optionable
Beta
1.31
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:OYST) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners